The following studies are currently recruiting patients

  • Masitinib in prostate cancer

The following studies will start recruitment in 2019:

  • Masitinib in Amyotrophic Lateral Sclerosis
  • Masitinib in indolent systemic severe mastocytosis
  • AB8939 in acute myeloid leukemia


If you wish to participate in this study, please contact us at the following address: